These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 3131563

  • 1. Generation of activated killer-like cells by OK-432-mediated production of interleukin 1, interleukin 2, and interferon-gamma in vitro.
    Ujiie T.
    Jpn J Exp Med; 1987 Dec; 57(6):333-8. PubMed ID: 3131563
    [Abstract] [Full Text] [Related]

  • 2. In vitro potentiation of human natural killer cell activity by a streptococcal preparation, OK-432: interferon and interleukin-2 participation in the stimulation with OK-432.
    Wakasugi H, Kasahara T, Minato N, Hamuro J, Miyata M, Morioka Y.
    J Natl Cancer Inst; 1982 Oct; 69(4):807-12. PubMed ID: 6181282
    [Abstract] [Full Text] [Related]

  • 3. Generation of activated killer (AK) cells by recombinant interleukin 2 (rIL 2) in collaboration with interferon-gamma (IFN-gamma).
    Itoh K, Shiiba K, Shimizu Y, Suzuki R, Kumagai K.
    J Immunol; 1985 May; 134(5):3124-9. PubMed ID: 2984283
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Enhanced generation of OK-432-induced killer cells by interleukin 2.
    Ujiie T.
    Jpn J Exp Med; 1987 Jun; 57(3):183-8. PubMed ID: 3500332
    [Abstract] [Full Text] [Related]

  • 6. Effects of the streptococcal preparation OK-432 on in vitro cytokine production of peripheral blood mononuclear cells in patients with chronic viral hepatitis.
    Yamashiki M, Nishimura A, Takase K, Nakano T, Kosaka Y.
    J Clin Lab Immunol; 1992 Jun; 38(2):73-82. PubMed ID: 1343350
    [Abstract] [Full Text] [Related]

  • 7. [Antitumor effect of OK-432 (1)--antitumor effect of OK-432 induced interferon-gamma (IFN gamma)].
    Saito M, Yamaguchi T, Aonuma E, Noda T, Edina T, Ishida N.
    Gan To Kagaku Ryoho; 1982 Nov; 9(11):2031-7. PubMed ID: 6820888
    [Abstract] [Full Text] [Related]

  • 8. Immunomodulating effects in vitro of interleukin-2 and interferon-gamma on human blood and bone marrow mononuclear cells.
    Kedar E, Rezai AR, Giorgi JV, Gale RP, Champlin RE, Mitsuyasu RT, Fahey JL.
    Nat Immun Cell Growth Regul; 1988 Nov; 7(1):13-30. PubMed ID: 2896298
    [Abstract] [Full Text] [Related]

  • 9. Augmentation by OK-432 of generation of culture-induced killer cells.
    Ujiie T.
    Jpn J Exp Med; 1987 Jun; 57(3):153-61. PubMed ID: 3682231
    [Abstract] [Full Text] [Related]

  • 10. Release of lymphokines after Epstein Barr virus infection in vitro. I. Sources of and kinetics of production of interferons and interleukins in normal humans.
    Lotz M, Tsoukas CD, Fong S, Dinarello CA, Carson DA, Vaughan JH.
    J Immunol; 1986 May 15; 136(10):3636-42. PubMed ID: 3009608
    [Abstract] [Full Text] [Related]

  • 11. New approach to management of malignant ascites with streptococcal preparation OK-432. III. OK-432 attracts natural killer cells through a chemotactic factor released from activated neutrophils.
    Hayashi Y, Torisu M.
    Surgery; 1990 Jan 15; 107(1):74-84. PubMed ID: 2404351
    [Abstract] [Full Text] [Related]

  • 12. Effect of streptococcal lyzate OK-432 on peripheral blood mononuclear cells in gastric cancer patients.
    Nakayama F, Iwagaki H, Gouchi A, Hizuta A, Isozaki H, Takakura N, Tanaka N.
    J Med; 1998 Jan 15; 29(3-4):199-215. PubMed ID: 9865458
    [Abstract] [Full Text] [Related]

  • 13. Interleukin-18 (IL-18) synergizes with IL-2 to enhance cytotoxicity, interferon-gamma production, and expansion of natural killer cells.
    Son YI, Dallal RM, Mailliard RB, Egawa S, Jonak ZL, Lotze MT.
    Cancer Res; 2001 Feb 01; 61(3):884-8. PubMed ID: 11221875
    [Abstract] [Full Text] [Related]

  • 14. Interleukin 18 induces the sequential activation of natural killer cells and cytotoxic T lymphocytes to protect syngeneic mice from transplantation with Meth A sarcoma.
    Micallef MJ, Tanimoto T, Kohno K, Ikeda M, Kurimoto M.
    Cancer Res; 1997 Oct 15; 57(20):4557-63. PubMed ID: 9377569
    [Abstract] [Full Text] [Related]

  • 15. [Successful adoptive immunotherapy with OK432-inducible activated natural killer cells on tumor-bearing mice].
    Yamaue H, Tanimura H, Iwahashi M, Tani M, Tsunoda T, Tabuse K.
    Nihon Gan Chiryo Gakkai Shi; 1989 Dec 20; 24(11):2546-55. PubMed ID: 2614190
    [Abstract] [Full Text] [Related]

  • 16. IFN-gamma production and cytotoxicity of IL-2-activated murine NK cells are differentially regulated by MHC class I molecules.
    Kubota A, Lian RH, Lohwasser S, Salcedo M, Takei F.
    J Immunol; 1999 Dec 15; 163(12):6488-93. PubMed ID: 10586040
    [Abstract] [Full Text] [Related]

  • 17. Oligodeoxynucleotides containing palindrome sequences with internal 5'-CpG-3' act directly on human NK and activated T cells to induce IFN-gamma production in vitro.
    Iho S, Yamamoto T, Takahashi T, Yamamoto S.
    J Immunol; 1999 Oct 01; 163(7):3642-52. PubMed ID: 10490958
    [Abstract] [Full Text] [Related]

  • 18. A macrophage derived blastogenic factor -MBF- induces cytokines and cytotoxic effectors in human peripheral blood mononuclear cells.
    Ausiello CM, Antonelli G, Spagnoli GC, Gentile M, Urbani F, Gitto M.
    J Biol Regul Homeost Agents; 1992 Oct 01; 6(1):8-14. PubMed ID: 1442174
    [Abstract] [Full Text] [Related]

  • 19. Endogenous IL-2 production by natural killer cells maintains cytotoxic and proliferative capacity following retroviral-mediated gene transfer.
    Miller JS, Tessmer-Tuck J, Blake N, Lund J, Scott A, Blazar BR, Orchard PJ.
    Exp Hematol; 1997 Oct 01; 25(11):1140-8. PubMed ID: 9328450
    [Abstract] [Full Text] [Related]

  • 20. Anti-tumor immune response induced by the fractions derived from OK-432, a streptococcal preparation, by using a monoclonal antibody TS-2 that neutralizes the interferon-gamma-inducing activity of OK-432: comparison between the TS-2-binding and TS-2-unbinding fraction.
    Oshikawa T, Okamoto M, Ohe G, Furuichi S, Nishikawa H, Uddin Ahmed S, Yoshida H, Moriya Y, Matsubara S, Ryoma Y, Saito M, Sato M.
    Int Immunopharmacol; 2003 May 01; 3(5):643-55. PubMed ID: 12757734
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.